Trial
NCT05679388
A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Chicago
Collaborators
—
Condition
Prostate Cancer
Intervention
Relugolix Pill
Why stopped
Terminated by the PI
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-19